Notably, intervention with 30 mg·kg−1 epimedin C decreased levels of FBG, HOMA-IR, and oral glucose tolerance, as well as the contents of MDA and LDL-C in T2DM mice, while it increased the hepatic glycogen, insulin, and HDL-C contents, as well as the activities of SOD and GSH-Px. This evidence concerns the gene SOD1 and type 2 diabetes mellitus.